FortuneRock Raises $24 Million for Protein Drug Development

FortuneRock (China) of Beijing completed a $24 million funding that it will use to advance its portfolio of novel protein drugs. Of the total, $20 million is earmarked for drug development and building a GMP manufacturing facility in Tianjin, which will be spun off into a separate company. The remaining $4 million will underwrite general corporate purposes, including a planned IPO. FortuneRock uses its technology platform to develop novel patent-protected, gene-based recombinant protein drugs that have substantial markets. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.